nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0818	0.137	CbGbCtD
Metoclopramide—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0769	0.129	CbGbCtD
Metoclopramide—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0769	0.129	CbGbCtD
Metoclopramide—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0696	0.116	CbGbCtD
Metoclopramide—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0696	0.116	CbGbCtD
Metoclopramide—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.06	0.1	CbGbCtD
Metoclopramide—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0583	0.0974	CbGbCtD
Metoclopramide—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0527	0.0881	CbGbCtD
Metoclopramide—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0527	0.0881	CbGbCtD
Metoclopramide—CYP11B2—blood plasma—acquired immunodeficiency syndrome	0.00978	0.146	CbGeAlD
Metoclopramide—HTR3A—nerve—acquired immunodeficiency syndrome	0.0062	0.0928	CbGeAlD
Metoclopramide—HTR4—brain—acquired immunodeficiency syndrome	0.00395	0.0591	CbGeAlD
Metoclopramide—DRD2—nerve—acquired immunodeficiency syndrome	0.00379	0.0568	CbGeAlD
Metoclopramide—CYP11B2—blood—acquired immunodeficiency syndrome	0.00358	0.0537	CbGeAlD
Metoclopramide—CYP11B1—blood—acquired immunodeficiency syndrome	0.00358	0.0537	CbGeAlD
Metoclopramide—CYP11B2—lymph node—acquired immunodeficiency syndrome	0.00215	0.0322	CbGeAlD
Metoclopramide—DRD3—nervous system—acquired immunodeficiency syndrome	0.00202	0.0302	CbGeAlD
Metoclopramide—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00194	0.0291	CbGeAlD
Metoclopramide—HTR3A—digestive system—acquired immunodeficiency syndrome	0.0018	0.027	CbGeAlD
Metoclopramide—CYP17A1—nervous system—acquired immunodeficiency syndrome	0.00178	0.0266	CbGeAlD
Metoclopramide—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00172	0.0258	CbGeAlD
Metoclopramide—HTR3A—blood—acquired immunodeficiency syndrome	0.00172	0.0257	CbGeAlD
Metoclopramide—CYP17A1—central nervous system—acquired immunodeficiency syndrome	0.00171	0.0256	CbGeAlD
Metoclopramide—DRD2—retina—acquired immunodeficiency syndrome	0.00157	0.0235	CbGeAlD
Metoclopramide—DRD3—brain—acquired immunodeficiency syndrome	0.00154	0.0231	CbGeAlD
Metoclopramide—HTR3A—lung—acquired immunodeficiency syndrome	0.00151	0.0225	CbGeAlD
Metoclopramide—HTR3A—nervous system—acquired immunodeficiency syndrome	0.00139	0.0209	CbGeAlD
Metoclopramide—CYP17A1—brain—acquired immunodeficiency syndrome	0.00136	0.0203	CbGeAlD
Metoclopramide—HTR3A—central nervous system—acquired immunodeficiency syndrome	0.00134	0.0201	CbGeAlD
Metoclopramide—CYP17A1—lymph node—acquired immunodeficiency syndrome	0.00131	0.0197	CbGeAlD
Metoclopramide—CHRM1—lung—acquired immunodeficiency syndrome	0.00114	0.0171	CbGeAlD
Metoclopramide—HTR3A—brain—acquired immunodeficiency syndrome	0.00107	0.016	CbGeAlD
Metoclopramide—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00106	0.0159	CbGeAlD
Metoclopramide—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.00102	0.0153	CbGeAlD
Metoclopramide—DRD2—lung—acquired immunodeficiency syndrome	0.000921	0.0138	CbGeAlD
Metoclopramide—DRD2—nervous system—acquired immunodeficiency syndrome	0.000853	0.0128	CbGeAlD
Metoclopramide—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000821	0.0123	CbGeAlD
Metoclopramide—CHRM1—brain—acquired immunodeficiency syndrome	0.00081	0.0121	CbGeAlD
Metoclopramide—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000676	0.00219	CcSEcCtD
Metoclopramide—Depression—Lamivudine—acquired immunodeficiency syndrome	0.000674	0.00219	CcSEcCtD
Metoclopramide—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.000668	0.00217	CcSEcCtD
Metoclopramide—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000663	0.00992	CbGeAlD
Metoclopramide—Leukopenia—Zidovudine—acquired immunodeficiency syndrome	0.000662	0.00215	CcSEcCtD
Metoclopramide—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.000662	0.00215	CcSEcCtD
Metoclopramide—Jaundice—Lamivudine—acquired immunodeficiency syndrome	0.000659	0.00214	CcSEcCtD
Metoclopramide—Hallucination—Ritonavir—acquired immunodeficiency syndrome	0.000658	0.00213	CcSEcCtD
Metoclopramide—DRD2—brain—acquired immunodeficiency syndrome	0.000652	0.00976	CbGeAlD
Metoclopramide—Tremor—Indinavir—acquired immunodeficiency syndrome	0.000645	0.00209	CcSEcCtD
Metoclopramide—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.000641	0.00208	CcSEcCtD
Metoclopramide—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.00064	0.00208	CcSEcCtD
Metoclopramide—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00064	0.00207	CcSEcCtD
Metoclopramide—Visual impairment—Ritonavir—acquired immunodeficiency syndrome	0.000637	0.00207	CcSEcCtD
Metoclopramide—Hallucination—Saquinavir—acquired immunodeficiency syndrome	0.000633	0.00205	CcSEcCtD
Metoclopramide—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000633	0.00205	CcSEcCtD
Metoclopramide—Agitation—Indinavir—acquired immunodeficiency syndrome	0.000632	0.00205	CcSEcCtD
Metoclopramide—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.000632	0.00205	CcSEcCtD
Metoclopramide—CYP2D6—blood—acquired immunodeficiency syndrome	0.000631	0.00945	CbGeAlD
Metoclopramide—Agranulocytosis—Lamivudine—acquired immunodeficiency syndrome	0.000631	0.00205	CcSEcCtD
Metoclopramide—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.00063	0.00204	CcSEcCtD
Metoclopramide—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00063	0.00204	CcSEcCtD
Metoclopramide—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000629	0.00204	CcSEcCtD
Metoclopramide—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.000628	0.00204	CcSEcCtD
Metoclopramide—Anxiety—Zidovudine—acquired immunodeficiency syndrome	0.000628	0.00204	CcSEcCtD
Metoclopramide—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.000621	0.00202	CcSEcCtD
Metoclopramide—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.00062	0.00201	CcSEcCtD
Metoclopramide—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.00062	0.00201	CcSEcCtD
Metoclopramide—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.000619	0.00201	CcSEcCtD
Metoclopramide—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.000618	0.002	CcSEcCtD
Metoclopramide—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.000613	0.00199	CcSEcCtD
Metoclopramide—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.000613	0.00199	CcSEcCtD
Metoclopramide—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00061	0.00198	CcSEcCtD
Metoclopramide—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.000609	0.00198	CcSEcCtD
Metoclopramide—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.000609	0.00198	CcSEcCtD
Metoclopramide—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.000608	0.00197	CcSEcCtD
Metoclopramide—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.000604	0.00196	CcSEcCtD
Metoclopramide—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000604	0.00196	CcSEcCtD
Metoclopramide—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000601	0.00195	CcSEcCtD
Metoclopramide—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000599	0.00194	CcSEcCtD
Metoclopramide—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.000598	0.00194	CcSEcCtD
Metoclopramide—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.000598	0.00194	CcSEcCtD
Metoclopramide—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000594	0.00193	CcSEcCtD
Metoclopramide—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.000593	0.00192	CcSEcCtD
Metoclopramide—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.00059	0.00191	CcSEcCtD
Metoclopramide—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00059	0.00191	CcSEcCtD
Metoclopramide—Anxiety—Indinavir—acquired immunodeficiency syndrome	0.000584	0.00189	CcSEcCtD
Metoclopramide—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000583	0.00189	CcSEcCtD
Metoclopramide—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.000575	0.00186	CcSEcCtD
Metoclopramide—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000574	0.00186	CcSEcCtD
Metoclopramide—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000574	0.00186	CcSEcCtD
Metoclopramide—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.000572	0.00185	CcSEcCtD
Metoclopramide—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000572	0.00185	CcSEcCtD
Metoclopramide—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000569	0.00185	CcSEcCtD
Metoclopramide—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000568	0.00184	CcSEcCtD
Metoclopramide—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000564	0.00183	CcSEcCtD
Metoclopramide—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000563	0.00183	CcSEcCtD
Metoclopramide—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000562	0.00182	CcSEcCtD
Metoclopramide—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000561	0.00182	CcSEcCtD
Metoclopramide—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.000559	0.00181	CcSEcCtD
Metoclopramide—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000557	0.00181	CcSEcCtD
Metoclopramide—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000554	0.0018	CcSEcCtD
Metoclopramide—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000554	0.0018	CcSEcCtD
Metoclopramide—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000553	0.00179	CcSEcCtD
Metoclopramide—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000553	0.00179	CcSEcCtD
Metoclopramide—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000552	0.00179	CcSEcCtD
Metoclopramide—Anxiety—Efavirenz—acquired immunodeficiency syndrome	0.000552	0.00179	CcSEcCtD
Metoclopramide—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000551	0.00179	CcSEcCtD
Metoclopramide—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00055	0.00178	CcSEcCtD
Metoclopramide—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00055	0.00178	CcSEcCtD
Metoclopramide—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000549	0.00178	CcSEcCtD
Metoclopramide—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000548	0.00178	CcSEcCtD
Metoclopramide—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000546	0.00177	CcSEcCtD
Metoclopramide—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000544	0.00176	CcSEcCtD
Metoclopramide—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000541	0.00176	CcSEcCtD
Metoclopramide—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000539	0.00175	CcSEcCtD
Metoclopramide—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000538	0.00175	CcSEcCtD
Metoclopramide—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000537	0.00174	CcSEcCtD
Metoclopramide—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000537	0.00174	CcSEcCtD
Metoclopramide—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000535	0.00174	CcSEcCtD
Metoclopramide—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000532	0.00173	CcSEcCtD
Metoclopramide—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00053	0.00172	CcSEcCtD
Metoclopramide—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000529	0.00172	CcSEcCtD
Metoclopramide—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000528	0.00171	CcSEcCtD
Metoclopramide—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000521	0.00169	CcSEcCtD
Metoclopramide—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000521	0.00169	CcSEcCtD
Metoclopramide—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000519	0.00168	CcSEcCtD
Metoclopramide—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000518	0.00168	CcSEcCtD
Metoclopramide—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000516	0.00167	CcSEcCtD
Metoclopramide—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000515	0.00167	CcSEcCtD
Metoclopramide—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000513	0.00167	CcSEcCtD
Metoclopramide—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000513	0.00166	CcSEcCtD
Metoclopramide—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000513	0.00767	CbGeAlD
Metoclopramide—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000512	0.00166	CcSEcCtD
Metoclopramide—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000512	0.00166	CcSEcCtD
Metoclopramide—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000509	0.00165	CcSEcCtD
Metoclopramide—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000508	0.00165	CcSEcCtD
Metoclopramide—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000508	0.00165	CcSEcCtD
Metoclopramide—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000508	0.00165	CcSEcCtD
Metoclopramide—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000508	0.00165	CcSEcCtD
Metoclopramide—Rash—Didanosine—acquired immunodeficiency syndrome	0.000505	0.00164	CcSEcCtD
Metoclopramide—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000504	0.00164	CcSEcCtD
Metoclopramide—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000504	0.00164	CcSEcCtD
Metoclopramide—Headache—Didanosine—acquired immunodeficiency syndrome	0.000501	0.00163	CcSEcCtD
Metoclopramide—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000501	0.00162	CcSEcCtD
Metoclopramide—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.0005	0.00162	CcSEcCtD
Metoclopramide—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000499	0.00162	CcSEcCtD
Metoclopramide—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000499	0.00162	CcSEcCtD
Metoclopramide—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000498	0.00162	CcSEcCtD
Metoclopramide—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000498	0.00161	CcSEcCtD
Metoclopramide—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000497	0.00161	CcSEcCtD
Metoclopramide—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000496	0.00161	CcSEcCtD
Metoclopramide—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000496	0.00161	CcSEcCtD
Metoclopramide—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000495	0.00161	CcSEcCtD
Metoclopramide—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000494	0.00739	CbGeAlD
Metoclopramide—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000492	0.0016	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000492	0.0186	CbGpPWpGaD
Metoclopramide—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000491	0.00159	CcSEcCtD
Metoclopramide—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000488	0.00158	CcSEcCtD
Metoclopramide—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000484	0.00157	CcSEcCtD
Metoclopramide—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000483	0.00157	CcSEcCtD
Metoclopramide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00048	0.00156	CcSEcCtD
Metoclopramide—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00048	0.00156	CcSEcCtD
Metoclopramide—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00048	0.00156	CcSEcCtD
Metoclopramide—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000478	0.00155	CcSEcCtD
Metoclopramide—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000477	0.00155	CcSEcCtD
Metoclopramide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000477	0.00155	CcSEcCtD
Metoclopramide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000475	0.00154	CcSEcCtD
Metoclopramide—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000475	0.00154	CcSEcCtD
Metoclopramide—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000474	0.00154	CcSEcCtD
Metoclopramide—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000473	0.00154	CcSEcCtD
Metoclopramide—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000473	0.00153	CcSEcCtD
Metoclopramide—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000473	0.00153	CcSEcCtD
Metoclopramide—DRD2—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000472	0.0178	CbGpPWpGaD
Metoclopramide—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000472	0.00153	CcSEcCtD
Metoclopramide—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.00047	0.00152	CcSEcCtD
Metoclopramide—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00047	0.00152	CcSEcCtD
Metoclopramide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000468	0.00152	CcSEcCtD
Metoclopramide—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000463	0.0015	CcSEcCtD
Metoclopramide—CHRM1—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000462	0.0175	CbGpPWpGaD
Metoclopramide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000461	0.0015	CcSEcCtD
Metoclopramide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000459	0.00149	CcSEcCtD
Metoclopramide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000459	0.00149	CcSEcCtD
Metoclopramide—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000458	0.00149	CcSEcCtD
Metoclopramide—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000458	0.00148	CcSEcCtD
Metoclopramide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000458	0.00148	CcSEcCtD
Metoclopramide—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000456	0.00148	CcSEcCtD
Metoclopramide—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000454	0.00147	CcSEcCtD
Metoclopramide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000453	0.00147	CcSEcCtD
Metoclopramide—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000453	0.00147	CcSEcCtD
Metoclopramide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000453	0.00147	CcSEcCtD
Metoclopramide—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000452	0.00147	CcSEcCtD
Metoclopramide—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000451	0.00146	CcSEcCtD
Metoclopramide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000451	0.00146	CcSEcCtD
Metoclopramide—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000448	0.00145	CcSEcCtD
Metoclopramide—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000446	0.00145	CcSEcCtD
Metoclopramide—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000444	0.00144	CcSEcCtD
Metoclopramide—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000439	0.00143	CcSEcCtD
Metoclopramide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000439	0.00142	CcSEcCtD
Metoclopramide—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000439	0.00142	CcSEcCtD
Metoclopramide—Rash—Stavudine—acquired immunodeficiency syndrome	0.000438	0.00142	CcSEcCtD
Metoclopramide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000438	0.00142	CcSEcCtD
Metoclopramide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000438	0.00142	CcSEcCtD
Metoclopramide—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000437	0.00142	CcSEcCtD
Metoclopramide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000437	0.00142	CcSEcCtD
Metoclopramide—Headache—Stavudine—acquired immunodeficiency syndrome	0.000435	0.00141	CcSEcCtD
Metoclopramide—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000435	0.00141	CcSEcCtD
Metoclopramide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000433	0.00141	CcSEcCtD
Metoclopramide—Rash—Abacavir—acquired immunodeficiency syndrome	0.000432	0.0014	CcSEcCtD
Metoclopramide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000431	0.0014	CcSEcCtD
Metoclopramide—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000431	0.0014	CcSEcCtD
Metoclopramide—Headache—Abacavir—acquired immunodeficiency syndrome	0.000429	0.00139	CcSEcCtD
Metoclopramide—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000427	0.00139	CcSEcCtD
Metoclopramide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000425	0.00138	CcSEcCtD
Metoclopramide—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000422	0.00137	CcSEcCtD
Metoclopramide—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000422	0.00137	CcSEcCtD
Metoclopramide—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000419	0.00136	CcSEcCtD
Metoclopramide—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000419	0.00136	CcSEcCtD
Metoclopramide—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000418	0.00136	CcSEcCtD
Metoclopramide—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000417	0.00135	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000414	0.0157	CbGpPWpGaD
Metoclopramide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000414	0.00134	CcSEcCtD
Metoclopramide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000414	0.00134	CcSEcCtD
Metoclopramide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000413	0.00134	CcSEcCtD
Metoclopramide—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000413	0.00134	CcSEcCtD
Metoclopramide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000409	0.00133	CcSEcCtD
Metoclopramide—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000407	0.00132	CcSEcCtD
Metoclopramide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000405	0.00131	CcSEcCtD
Metoclopramide—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000403	0.00131	CcSEcCtD
Metoclopramide—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000403	0.00131	CcSEcCtD
Metoclopramide—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000403	0.00131	CcSEcCtD
Metoclopramide—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000403	0.00131	CcSEcCtD
Metoclopramide—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000402	0.0013	CcSEcCtD
Metoclopramide—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000401	0.0013	CcSEcCtD
Metoclopramide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000399	0.0013	CcSEcCtD
Metoclopramide—CYP2D6—brain—acquired immunodeficiency syndrome	0.000392	0.00587	CbGeAlD
Metoclopramide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000391	0.00127	CcSEcCtD
Metoclopramide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00039	0.00126	CcSEcCtD
Metoclopramide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00039	0.00126	CcSEcCtD
Metoclopramide—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000387	0.00126	CcSEcCtD
Metoclopramide—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000384	0.00125	CcSEcCtD
Metoclopramide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000384	0.00125	CcSEcCtD
Metoclopramide—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000383	0.00124	CcSEcCtD
Metoclopramide—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000381	0.00124	CcSEcCtD
Metoclopramide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000381	0.00124	CcSEcCtD
Metoclopramide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00038	0.00123	CcSEcCtD
Metoclopramide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000378	0.00123	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000375	0.0142	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000374	0.00121	CcSEcCtD
Metoclopramide—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000373	0.00121	CcSEcCtD
Metoclopramide—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000372	0.00121	CcSEcCtD
Metoclopramide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000372	0.00121	CcSEcCtD
Metoclopramide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000371	0.0012	CcSEcCtD
Metoclopramide—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000371	0.0012	CcSEcCtD
Metoclopramide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000364	0.00118	CcSEcCtD
Metoclopramide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000363	0.00118	CcSEcCtD
Metoclopramide—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000359	0.00116	CcSEcCtD
Metoclopramide—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000359	0.00116	CcSEcCtD
Metoclopramide—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000357	0.00116	CcSEcCtD
Metoclopramide—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000355	0.00115	CcSEcCtD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000355	0.0134	CbGpPWpGaD
Metoclopramide—Rash—Indinavir—acquired immunodeficiency syndrome	0.000354	0.00115	CcSEcCtD
Metoclopramide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000354	0.00115	CcSEcCtD
Metoclopramide—Headache—Indinavir—acquired immunodeficiency syndrome	0.000352	0.00114	CcSEcCtD
Metoclopramide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000351	0.00114	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000351	0.0133	CbGpPWpGaD
Metoclopramide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000347	0.00113	CcSEcCtD
Metoclopramide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000346	0.00112	CcSEcCtD
Metoclopramide—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.00111	CcSEcCtD
Metoclopramide—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000341	0.00111	CcSEcCtD
Metoclopramide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000337	0.00109	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000336	0.0127	CbGpPWpGaD
Metoclopramide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000336	0.00109	CcSEcCtD
Metoclopramide—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000335	0.00109	CcSEcCtD
Metoclopramide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000334	0.00108	CcSEcCtD
Metoclopramide—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000334	0.00108	CcSEcCtD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000334	0.0126	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000333	0.00108	CcSEcCtD
Metoclopramide—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000332	0.00108	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000328	0.0124	CbGpPWpGaD
Metoclopramide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000324	0.00105	CcSEcCtD
Metoclopramide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000321	0.00104	CcSEcCtD
Metoclopramide—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00032	0.00104	CcSEcCtD
Metoclopramide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00032	0.00104	CcSEcCtD
Metoclopramide—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000318	0.00103	CcSEcCtD
Metoclopramide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000318	0.00103	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000315	0.0119	CbGpPWpGaD
Metoclopramide—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.00102	CcSEcCtD
Metoclopramide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00101	CcSEcCtD
Metoclopramide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000309	0.001	CcSEcCtD
Metoclopramide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000309	0.001	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000304	0.0115	CbGpPWpGaD
Metoclopramide—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000302	0.000978	CcSEcCtD
Metoclopramide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000299	0.000969	CcSEcCtD
Metoclopramide—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000296	0.00096	CcSEcCtD
Metoclopramide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000296	0.000959	CcSEcCtD
Metoclopramide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.000957	CcSEcCtD
Metoclopramide—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000294	0.000954	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000286	0.0108	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000286	0.0108	CbGpPWpGaD
Metoclopramide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.000925	CcSEcCtD
Metoclopramide—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000285	0.000924	CcSEcCtD
Metoclopramide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000285	0.000924	CcSEcCtD
Metoclopramide—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.000918	CcSEcCtD
Metoclopramide—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000279	0.000905	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000277	0.0105	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000272	0.0103	CbGpPWpGaD
Metoclopramide—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000272	0.000882	CcSEcCtD
Metoclopramide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000272	0.000881	CcSEcCtD
Metoclopramide—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.000876	CcSEcCtD
Metoclopramide—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000871	CcSEcCtD
Metoclopramide—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000831	CcSEcCtD
Metoclopramide—HTR4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000256	0.00968	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000254	0.00962	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000251	0.00949	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00025	0.00944	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000246	0.00929	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	0.000234	0.00883	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000231	0.00875	CbGpPWpGaD
Metoclopramide—HTR4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000229	0.00865	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000218	0.00823	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000218	0.00823	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000217	0.00822	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000213	0.00804	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000207	0.00784	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000199	0.00751	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000196	0.00741	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	0.000194	0.00735	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000192	0.00727	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000192	0.00727	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000191	0.00723	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000187	0.00707	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00018	0.00679	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000166	0.00626	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TAT—acquired immunodeficiency syndrome	0.000165	0.00625	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000152	0.00575	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000151	0.00572	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000149	0.00564	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000149	0.00563	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TAT—acquired immunodeficiency syndrome	0.000142	0.00538	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00014	0.00531	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00014	0.00528	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000137	0.0052	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000137	0.00517	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000135	0.00509	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TAT—acquired immunodeficiency syndrome	0.000133	0.00504	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000131	0.00497	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000131	0.00496	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000131	0.00496	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000131	0.00495	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00013	0.0049	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000128	0.00485	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000126	0.00475	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000126	0.00475	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000123	0.00465	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000123	0.00465	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000123	0.00464	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000122	0.00461	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000121	0.00458	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000119	0.00449	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000116	0.00438	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000114	0.0043	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000113	0.00428	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000113	0.00428	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000112	0.00422	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000112	0.00422	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000111	0.0042	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000107	0.00404	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000105	0.00398	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000105	0.00396	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00395	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00395	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000102	0.00387	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.0001	0.0038	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.0001	0.0038	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.99e-05	0.00378	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.91e-05	0.00375	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.81e-05	0.00371	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.7e-05	0.00367	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.6e-05	0.00363	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.39e-05	0.00355	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.36e-05	0.00354	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.35e-05	0.00353	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.32e-05	0.00353	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.22e-05	0.00349	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.19e-05	0.00348	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.12e-05	0.00345	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9e-05	0.0034	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	8.5e-05	0.00321	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.5e-05	0.00321	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.49e-05	0.00321	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.45e-05	0.0032	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.43e-05	0.00319	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.37e-05	0.00317	CbGpPWpGaD
Metoclopramide—DRD3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.35e-05	0.00316	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.31e-05	0.00314	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.99e-05	0.00302	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.99e-05	0.00302	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.95e-05	0.00301	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.95e-05	0.00301	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.94e-05	0.003	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.82e-05	0.00296	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.82e-05	0.00296	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.76e-05	0.00294	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.76e-05	0.00293	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.65e-05	0.00289	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.64e-05	0.00289	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.57e-05	0.00286	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.15e-05	0.00271	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.15e-05	0.0027	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.02e-05	0.00266	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.02e-05	0.00265	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7e-05	0.00265	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.88e-05	0.0026	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.6e-05	0.0025	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.6e-05	0.0025	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	6.47e-05	0.00245	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.47e-05	0.00245	CbGpPWpGaD
Metoclopramide—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.39e-05	0.00242	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.33e-05	0.00239	CbGpPWpGaD
Metoclopramide—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.25e-05	0.00236	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.08e-05	0.0023	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.08e-05	0.0023	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.07e-05	0.0023	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.05e-05	0.00229	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.02e-05	0.00228	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.95e-05	0.00225	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.95e-05	0.00225	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.95e-05	0.00225	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.94e-05	0.00225	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.81e-05	0.0022	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.79e-05	0.00219	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.67e-05	0.00214	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.58e-05	0.00211	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.47e-05	0.00207	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.45e-05	0.00206	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.37e-05	0.00203	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.36e-05	0.00203	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.26e-05	0.00199	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.21e-05	0.00197	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.02e-05	0.0019	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.94e-05	0.00187	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.87e-05	0.00184	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.8e-05	0.00181	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.78e-05	0.00181	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.63e-05	0.00175	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.59e-05	0.00173	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.59e-05	0.00173	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.53e-05	0.00171	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.52e-05	0.00171	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.49e-05	0.0017	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.49e-05	0.0017	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.42e-05	0.00167	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.00164	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.17e-05	0.00158	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.15e-05	0.00157	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.08e-05	0.00154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.08e-05	0.00154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.08e-05	0.00154	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.67e-05	0.00139	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.66e-05	0.00138	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	3.6e-05	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.59e-05	0.00136	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.58e-05	0.00135	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.51e-05	0.00133	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.51e-05	0.00133	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.46e-05	0.00131	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.44e-05	0.0013	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.44e-05	0.0013	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.43e-05	0.0013	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.43e-05	0.0013	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.00129	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.37e-05	0.00127	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.36e-05	0.00127	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.36e-05	0.00127	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.32e-05	0.00126	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.25e-05	0.00123	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.17e-05	0.0012	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.12e-05	0.00118	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.12e-05	0.00118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.11e-05	0.00117	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.1e-05	0.00117	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.00116	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.06e-05	0.00116	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.06e-05	0.00116	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.05e-05	0.00116	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.05e-05	0.00116	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ALB—acquired immunodeficiency syndrome	2.88e-05	0.00109	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.83e-05	0.00107	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.8e-05	0.00106	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.65e-05	0.001	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.61e-05	0.000989	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.61e-05	0.000988	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.6e-05	0.000983	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.59e-05	0.000981	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.58e-05	0.000974	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.56e-05	0.000969	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.56e-05	0.000968	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.52e-05	0.000953	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ALB—acquired immunodeficiency syndrome	2.48e-05	0.000939	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.46e-05	0.000929	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.41e-05	0.000911	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.41e-05	0.000911	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.37e-05	0.000898	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.000891	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.34e-05	0.000884	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.32e-05	0.000879	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ALB—acquired immunodeficiency syndrome	2.32e-05	0.000878	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.31e-05	0.000872	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.29e-05	0.000866	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.17e-05	0.00082	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.000809	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.12e-05	0.000802	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.09e-05	0.000792	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.96e-05	0.000742	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.92e-05	0.000726	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.84e-05	0.000697	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.84e-05	0.000697	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.83e-05	0.000693	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.000683	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.8e-05	0.000682	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.8e-05	0.000682	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000673	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.000624	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000611	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000581	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.4e-05	0.00053	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.000522	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.37e-05	0.000519	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.36e-05	0.000515	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.000511	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000504	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.000478	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.000468	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000467	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000457	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.54e-06	0.000361	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.49e-06	0.000359	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.3e-06	0.000276	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.26e-06	0.000275	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.14e-06	0.00027	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.11e-06	0.000269	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	6.28e-06	0.000238	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.61e-06	0.000212	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.29e-06	0.000162	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.2e-06	0.000159	CbGpPWpGaD
